With emphasis on biotechnology, Trevor focuses his portfolio on undervalued micro and small-cap companies. As a contributor to TalkMarkets, he hopes to elucidate undervalued companies that are exploring revolutionary treatment modalities for a wide spectrum of rare and devastating medical ... more
With emphasis on biotechnology, Trevor focuses his portfolio on undervalued micro and small-cap companies. As a contributor to TalkMarkets, he hopes to elucidate undervalued companies that are exploring revolutionary treatment modalities for a wide spectrum of rare and devastating medical conditions. Trevor strives for an open, honest and insightful dialogue with expert and amateur readers alike. He appreciates your comments and encourages readers to follow him and stay updated on his newest stock ideas.
lessAPHB | AMPLIPHI BIOSCIENCES |
ARNA | Arena Pharmaceuticals, Inc. |
BLFS | BIOLIFE SOLUTIONS |
CHK | Chesapeake Energy Corporation |
ECYT | Endocyte Inc. |
HZNP | Horizon Pharma |
IAG | IAMGOLD Corporation |
KOG | Kodiak Oil & Gas Corp |
OPXA | Opexa Therapeutics Inc. |
OXGN | OXiGENE, Inc. |
RNN | Rexahn Pharmaceuticals Inc |
RXII | RXi Pharmaceuticals Corporation |
SYN | Synthetic Biologics |
Legal Intern | |
Airbus DS Communications | |
May 2016 - Present (6 years 4 months) |
Contributor | |
Seeking Alpha | |
March 2014 - Present (8 years 6 months) |
Newsletter Provider | |
The Biotech Rundown | |
April 2014 - Present (8 years 5 months) |
Freelance Writer | |
The Motley Fool | |
June 2014 - Present (8 years 3 months) |
Contributor | |
TalkMarkets | |
May 2014 - Present (8 years 4 months) |
University of Colorado School of Law | |
Doctor of Law (J.D.) | |
2015 / 2018 | |
Law |
University of California, Davis | |
Bachelors in Letters and Science (Highest Honors Pending) | |
2011 / 2014 | |
Political Science, Contemporary Leadership |
Why AstraZeneca Could Outperform | |
Trevor Lowenthal | |
The Motley Fool | |
06/06/2014 |
BioLife Solutions: A Heavily Discounted High Growth Opportunity | |
Trevor Lowenthal | |
Seeking Alpha | |
05/22/2014 |
Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification | |
Trevor Lowenthal | |
Seeking Alpha | |
05/13/2014 |
Opexa Therapeutics: An Optimal Buyout Candidate Pending Successful Topline Results From Abili-T | |
Trevor Lowenthal | |
Seeking Alpha | |
04/29/2014 |
The Bull Case For Oragenics: Buy The 30% Discount, Hold For Long-Term Success Of The Lantibiotic Program | |
Trevor Lowenthal | |
Seeking Alpha | |
04/22/2014 |
AmpliPhi Biosciences: A Speculative Play In Biopharmaceuticals Too Compelling To Ignore | |
Trevor Lowenthal | |
Seeking Alpha | |
04/10/2014 |
OXiGENE Incorporated: An Undervalued Opportunity In Biopharmaceuticals | |
Trevor Lowenthal | |
Seeking Alpha | |
03/25/2014 |
Drain the Swamp | |
Trevor Lowenthal | |
Davis Political Review | |
07/01/2013 |
Latest Comments
Put Options: The Smart Way To Buy
Hi Chad, thanks for the article! Really informative. Just curious, do you recommend selling puts on any particular stocks? Also, what do you think about conservative put investing? By that I mean selling puts way in the money for a very small premium, so essentially there is little probability that you will pick up the shares?
Stocks That Have Investors (Including Me) Excited
Nevertheless, it was a gamble. I don't like AMZN as a long-term investment because I don't think the company's value proposition is convincing.
Stocks That Have Investors (Including Me) Excited
I agree with you, to some extent. I sort of took a gamble on an AMZN $310 Jan 17 Call a month or so ago, and it really paid off. Certainly gains to be made on these types of stocks.
Stocks That Have Investors (Including Me) Excited
Good to know, thanks!
Stocks That Have Investors (Including Me) Excited
Hi Joshua, any thoughts on where you think AMZN is headed? Just hit a high in intraday trading today. Thanks!
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
Thanks very much! That helps.
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
Fantastic article. In addition to Alexis' question, I have a few of my own. I would like to know more about your research on the license termination by Merck for the oral candidate. Any chance you could either construct another article discussing your research or elaborate here?
Also, let's say hypothetically that the FDA rejects the product. Is the company's business sustainable on alternative revenues alone?
4 years stretches far beyond the average review time for such products. Do you attribute this to a lapse in the regulatory process, or is there more to the story beyond the enrollment halt?
Thanks in advance.
EnteroMedics Spikes Up Following FDA Approval Of Neuroblocking Obesity Device
Also, I see the PPS consolidating in the next day or so. Very difficult to predict how post-approval stocks will act, but the trend is inherently negative. Look at Arena, Vivus, Orexigen, and Chelsea Therapeutics
EnteroMedics Spikes Up Following FDA Approval Of Neuroblocking Obesity Device
Hi Alexis, I believe the stock is down today because shareholders have realized that the extreme cost of the device ($15,000 - $30,000 per unit) could hinder sales uptake. You can read more about this on Bloomberg:
www.bloomberg.com/.../...-full-to-cost-15-000.html
Ligand Partner Receives Orphan Drug Designation
Thanks for commenting! I appreciate your insight, and I completely agree with you. I despise the fact that the said hedge fund is attempting to manipulate shareholders into believing that Ligand has no value, only to squeeze out short term gains on their massive short position. I will say, however, that Ligand is one company that always has something happening. Although there might be a vacuum of fundamental news in respect to the overall market, Ligand should benefit from a myriad of clinical updates for its respective partnerships and collaborations.